Modernatx, Inc.

This study tests an updated COVID-19 vaccine (mRNA-1283) designed to protect against current virus variants. About 832 people aged 12 and older, especially those at higher risk, will receive the vaccine. Researchers will measure immune response and monitor for side effects to ens…

This study tested an mRNA vaccine (mRNA-1345) against respiratory syncytial virus (RSV) in 360 pregnant women. The goal was to see if the vaccine is safe for mothers and their babies, and whether it triggers an immune response that could protect infants after birth. Participants …

This study tested an experimental mRNA vaccine (mRNA-1647) for cytomegalovirus (CMV) in healthy teens (9–15 years) and young women (16–25 years). The goal was to see if the vaccine is safe and triggers a strong immune response. Participants received either the vaccine or a placeb…

This study tested an experimental mRNA vaccine called mRNA-1647 to see if it is safe and triggers an immune response against cytomegalovirus (CMV). The trial involved 315 healthy adults aged 18 to 40, some of whom had never been exposed to CMV. Researchers measured side effects a…

This study tested the safety and immune response of several Moderna mRNA vaccines for COVID-19, seasonal flu, RSV, and CMV in 308 healthy adults aged 18 to 75. Researchers monitored side effects and measured antibody levels after vaccination. The goal was to ensure the vaccines a…

This study is a long-term follow-up of a phase 2 trial testing Moderna's mRNA-1647 vaccine against cytomegalovirus (CMV). It involves 135 adults who previously received the vaccine or a placebo. Researchers are checking how long the immune response lasts and whether a booster dos…

This phase 3 study tested an mRNA vaccine called mRNA-1345 to protect against respiratory syncytial virus (RSV) in adults aged 50 and older. Over 3,300 participants received the vaccine alone, with a flu shot, or with a COVID-19 booster. The trial also looked at a booster dose on…

This early-stage trial tested several experimental mRNA vaccines that aim to protect against both influenza and SARS-CoV-2 in a single injection. About 1,758 healthy adults aged 18 to under 80 took part. The main goals were to check safety and measure the immune response, with re…

This study tested a new combination vaccine called mRNA-1083 that aims to protect against both COVID-19 and the flu with a single shot. It involved 2,457 healthy adults aged 50 and older in Japan, Taiwan, and South Korea. The main goals were to check how well the vaccine triggers…

This study tested two updated mRNA COVID-19 vaccines in over 1,800 children aged 6 months to under 6 years. The vaccines were given as a primary series or booster to see if they are safe and trigger a strong immune response against variants like Omicron. The goal is to protect yo…

This study tested a new mRNA-based flu vaccine (mRNA-1010) in 172 healthy adults aged 18-50 and 65-80. The goal was to check its safety and how well it triggers the immune system compared to standard flu vaccines. Results help determine if the vaccine is safe and effective enough…

This study tested a new combination vaccine called mRNA-1083 that aims to protect against both flu and COVID-19 in a single shot. About 1,320 adults aged 18 to 64 took part. Researchers measured the immune response and checked for side effects to see if the combo vaccine works as…

This study tested a single shot that aims to protect against both COVID-19 and the flu. About 932 adults aged 50 to 64 received the experimental mRNA-1083 vaccine. Researchers checked for side effects and measured antibody levels one month after vaccination to see how well the va…

This study tested Moderna's experimental Zika vaccine, mRNA-1893, in 808 healthy adults aged 18 to 65. Participants received one of two doses or a placebo, and researchers monitored side effects and immune responses. The goal was to confirm the vaccine's safety and ability to pro…

This completed Moderna trial tested the mRNA-1273 COVID-19 vaccine in over 4,300 healthy adolescents aged 12 to 17. The study looked at safety, side effects, and how well the vaccine works to prevent COVID-19. Participants received either the vaccine or a placebo, and some later …

This large Phase 3 trial tested an experimental mRNA-based flu vaccine (mRNA-1010) against standard flu shots in over 40,000 adults aged 50 and older. The goal was to see if the new vaccine is safer and better at preventing flu-like illness caused by influenza A or B. Researchers…

This study tested two new mRNA vaccine candidates designed to prevent Lyme disease. It involved 807 healthy adults to see if the vaccines were safe and if they triggered a good immune response against the bacteria that causes Lyme. The study compared different doses of the vaccin…

This study tested an experimental mRNA vaccine (mRNA-1608) in 303 healthy adults aged 18 to 55 with recurrent genital herpes caused by HSV-2. The goal was to see if the vaccine is safe and can reduce the number of outbreaks. Participants received different doses of the vaccine or…

This study tested a new mRNA booster shot (mRNA-1345) in 507 adults aged 60 and older who had already received a licensed RSV vaccine at least a year earlier. The goal was to see if the booster is safe and boosts the immune system's ability to fight RSV. Researchers measured side…

This large Phase 3 trial compared a new experimental mRNA COVID-19 vaccine (mRNA-1283) with Moderna's original vaccine (mRNA-1273) in over 13,500 people aged 12 and older. The goal was to see if the new vaccine is safer, triggers a better immune response, and prevents COVID-19 at…

This completed Phase 4 study tested whether an updated COVID-19 vaccine (mRNA-1273.712) affects heart muscle in healthy people aged 12 to 30. Researchers measured a heart enzyme called troponin in 1,000 participants who received either the vaccine or a placebo. The goal was to se…